Your browser doesn't support javascript.
Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes.
Schnell, Oliver; Battelino, Tadej; Bergenstal, Richard; Blüher, Matthias; Böhm, Michael; Brosius, Frank; Carr, Richard D; Ceriello, Antonio; Forst, Thomas; Giorgino, Francesco; Guerci, Bruno; Heerspink, Hiddo J L; Itzhak, Baruch; Ji, Linong; Kosiborod, Mikhail; Lalic, Nebojsa; Lehrke, Michael; Marx, Nikolaus; Nauck, Michael; Rodbard, Helena W; Rosano, Giuseppe M C; Rossing, Peter; Rydén, Lars; Santilli, Francesca; Schumm-Draeger, Petra-Maria; Vandvik, Per Olav; Vilsbøll, Tina; Wanner, Christoph; Wysham, Carol; Standl, Eberhard.
  • Schnell O; Forschergruppe Diabetes e. V., Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Munich, Germany. oliver.schnell@lrz.uni-muenchen.de.
  • Battelino T; University Medical Center, Ljubljana, Slovenia.
  • Bergenstal R; University Children's Hospital, Ljubljana, Slovenia.
  • Blüher M; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
  • Böhm M; International Diabetes Center at Park Nicollet, Health Partners, Minneapolis, MN, USA.
  • Brosius F; Department of Medicine, University of Leipzig, Leipzig, Germany.
  • Carr RD; Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Saarland University, Homburg, Germany.
  • Ceriello A; College of Medicine, University of Arizona, Tuscon, AZ, USA.
  • Forst T; University College London, London, UK.
  • Giorgino F; IRCCS MultiMedica, Milan, Italy.
  • Guerci B; CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany.
  • Heerspink HJL; Department of Emergency and Organ Transplantation, University of Bari Aldo Moro, Bari, Italy.
  • Itzhak B; Department of Endocrinology Diabetology and Nutrition, Nancy University Hospital, Nancy, France.
  • Ji L; Faculty of Medicine, University of Lorraine, Vandoeuvre-lès-Nancy, France.
  • Kosiborod M; Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
  • Lalic N; Clalit Health Services and Technion Faculty of Medicine, Haifa, Israel.
  • Lehrke M; Peking University People's Hospital, Xicheng District, Beijing, China.
  • Marx N; Cardiometabolic Center of Excellence, University of Missouri-Kansas City, Kansas City, MO, USA.
  • Nauck M; Faculty of Medicine, Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, University of Belgrade, Belgrade, Serbia.
  • Rodbard HW; Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany.
  • Rosano GMC; Department of Internal Medicine I, University Hospital Aachen, Aachen, Germany.
  • Rossing P; Diabetes Division, Katholisches Klinikum Bochum, St. Josef-Hospital, Ruhr University Bochum, Bochum, Germany.
  • Rydén L; Endocrine and Metabolic Consultants, Rockville, MD, USA.
  • Santilli F; Department of Medical Sciences, IRCCS, Rome, Italy.
  • Schumm-Draeger PM; Steno Diabetes Center Copenhagen, Herlev, Denmark.
  • Vandvik PO; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Vilsbøll T; Department of Medicine K2, Karolinska Institute, Stockholm, Sweden.
  • Wanner C; Department of Medicine and Aging, Hospital and, University of Chieti, Chieti, Italy.
  • Wysham C; Centre Internal Medicine Fünf Höfe, Munich, Germany.
  • Standl E; Department of Medicine, Lovisenberg Diaconal Hospital, Oslo, Norway.
Cardiovasc Diabetol ; 21(1): 50, 2022 04 08.
Article in English | MEDLINE | ID: covidwho-1779649
ABSTRACT
The 7th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Renal, and Glycemic Outcomes, was held virtually on November 18-19, 2021. Pursuing the tradition of the previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed CVOTs. This year's focus was placed on the outcomes of EMPEROR-Preserved, FIGARO-DKD, AMPLITUDE-O, SURPASS 1-5, and STEP 1-5. Trial implications for diabetes and obesity management and the impact on new treatment algorithms were highlighted for endocrinologists, diabetologists, cardiologists, nephrologists, and general practitioners. Discussions evolved from outcome trials using SGLT2 inhibitors as therapy for heart failure, to CVOTs with nonsteroidal mineralocorticoid receptor antagonists and GLP-1 receptor agonists. Furthermore, trials for glycemic and overweight/obesity management, challenges in diabetes management in COVID-19, and novel guidelines and treatment strategies were discussed.Trial registration The 8th Cardiovascular Outcome Trial Summit will be held virtually on November 10-11, 2022 ( http//www.cvot.org ).
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Diseases / Diabetes Mellitus Type of study: Prognostic study / Qualitative research / Randomized controlled trials Limits: Humans Language: English Journal: Cardiovasc Diabetol Journal subject: Vascular Diseases / Cardiology / Endocrinology Year: 2022 Document Type: Article Affiliation country: S12933-022-01481-0

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Diseases / Diabetes Mellitus Type of study: Prognostic study / Qualitative research / Randomized controlled trials Limits: Humans Language: English Journal: Cardiovasc Diabetol Journal subject: Vascular Diseases / Cardiology / Endocrinology Year: 2022 Document Type: Article Affiliation country: S12933-022-01481-0